Clinical trials: sponsored by Ohio State University Comprehensive Cancer Center
- Sponsor Ohio State University Comprehensive Cancer Center
- Funder type Industry (pharma, biotech, devices)
Cancer Care Recipient, Observational Study
Bridging the Gap: Enhancing Cancer Care for Underserved Populations With the Veris Health Cancer Care Platform
The proposed study aims to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients receiving outpatient cancer therapy.
- Trial name
- NCT07396064
- Testing
- Veris Health Inc. Application
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VERIS HEALTH INC
Mycosis Fungoides
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
This study evaluates the effectiveness - as judged by complete response - of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a…
- Trial name
- Resimmune® (NCT02943642)
- Testing
- A-dmDT390-bisFv(UCHT1), Vorinostat
- Sponsor
- Virogen Biotechnology Inc.
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Lymphoma, Large B-Cell, Diffuse
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
The aim of this non-interventional multi-center study is to evaluate quality of life (QOL) and other patient reported outcomes (PROs) among adults with diffuse large b-cell lymphoma (DLBCL) following Chimeric Antigen Receptor…
- Trial name
- NCT05199961
- Testing
- Digital Health Coaching
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pack Health
Breast Cancer
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients.
- Trial name
- MINT (NCT01501487)
- Testing
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
- Where
- 9 sites in United States
- Volunteers
- 226 people
- Sponsor
- Agendia